Nanoparticle therapy trial


Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company announced that its lead compound NBTXR3 had received the go-ahead from the French Medicine Agency (AFSSAPS) to enter its first clinical Phase I trial. Up to 60% of cancer patients undergo radio­therapy, a treatment in which radiation is absorbed by water molecules in the tumour’s cells. This creates free radicals that cause damage and lead to local cell death. The interaction is inefficient however, as the majority of radiation energy is not converted into free radicals. Nanobiotix’s solution is to inject a nanoparticle with a diameter of around 50 nanometers and a heavy oxide core that increases radiation absorption by a factor of 10,000. The nano­particles cause the release of many more free radicals than water, which amplifies the effect of radiation on the tumour cell. Nanobio­tix’s lead program NBTXR3 is a formulation for intra­tumoural injection. A special coating, which is key to the process, allows the nanoparticles to enter the target cells. The company believes that potentially any tumour type would respond to treatment with their nanoparticles in combination with X-ray radiation.



Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%


  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%


  • PROTHENA PLC (IE)49.60 USD24.2%
  • DBV Technologies (F)52.00 EUR22.1%
  • VERONA PHARMA (UK)4.92 GBP15.8%


  • OREXO (S)68.50 SEK-24.1%
  • NORDIC NANOVECTOR (N)27.00 NOK-23.3%


  • ADOCIA (F)64.00 EUR364.8%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.69 EUR350.0%


  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-69.8%
  • NEOVACS (F)1.11 EUR-67.3%

No liability assumed, Date: 30.06.2015

Current issue

All issues